A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.
A memory B cell response to Zika virus in dengue-infected patients produced antibodies that were poorly neutralizing in vitro and instead enhanced infection.
A family of broadly neutralizing antibodies from a chronically infected donor provides a schematic for designing vaccines and treatments that target multiple strains of the virus.